Aurinia Pharmaceuticals Inc (AUPH NASDAQ) stock market data APIs
$15.6814
-0.41(-2.6%)
as of November 21, 2025
Try our APIs with
free plan!
Aurinia Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Prev. Close
15.6814
Open
15.2693
High
15.7185
Low
14.9446
52 wk Range
6.55-16.2
Market Cap
2 067 M
P/E Ratio
28
Shares Outstanding
132 M
Revenue
266 M
EPS
0.23
Beta
1.457
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aurinia Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aurinia Pharmaceuticals Inc data using free add-ons & libraries
Get Aurinia Pharmaceuticals Inc Fundamental Data
Aurinia Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 266 M
- EBITDA: 101 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: 0.1467
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aurinia Pharmaceuticals Inc News
New
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points. EXTON, PA, Nov. 19, 2025 ...
Vera Therapeutics Stock Earns RS Rating Upgrade
Vera Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 76 to 83. Looking For The Best Stocks To Buy And Watch? Start Here IBD's unique ...
Edgewise Therapeutics Stock Earns RS Rating Upgrade
Edgewise Therapeutics stock now meets that criteria, with an increase from 80 to 88 Monday. Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or hi...
Sector Update: Health Care Stocks Decline in Afternoon Trading
Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
